News
Just published in @nature : SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. Read the manuscript here: https://buff.ly/3gyHR8K
Two injections of an mRNA-based #SARSCoV2 vaccine elicited high levels of NAb and Th1 CD4 T-cell responses in rhesus macaques. Two days after challenge with intranasal and intratracheal virus, viral replication was undetectable in BAL fluid and nasal secretions. #COVID19
Moderna Announces Publication in The New England Journal of Medicine of Non-Human Primate Preclinical Viral Challenge Study of its mRNA Vaccine Against COVID-19 (mRNA-1273) | Moderna, Inc.
Moderna Announces Publication in The New England Journal of Medicine of Non-Human Primate Preclinical Viral Challenge Study of its mRNA Vaccine Against COVID-19 (mRNA-1273) | Moderna, Inc.
mRNA-1273 induced robust neutralizing antibodies and dose dependent increases in T cell responses mRNA-1273 led to protection against SARS-CoV-2 infec...
investors.modernatx.com
A Phase 3 clinical trial of investigational vaccine mRNA-1273 to prevent #COVID19, co-developed by #NIH @NIAIDNews and @Moderna, has begun. The multisite trial will assess preventive power, enrolling 30k+ volunteers. Learn more: https://www.nih.gov/news-events/news-releases/phase-3-clinical-trial-investigational-vaccine-covid-19-begins
As mRNA vaccines move to phase 3. We believe that mRNA is a powerful platform to generate therapeutics against SARS-COV2.
Rapid generation of circulating and mucosal decoy ACE2 using mRNA nanotherapeutics for the potential treatment of SARS-CoV-2 https://biorxiv.org/cgi/content/short/2020.07.24.205583v1 #bioRxiv
Excited to share our response to COVID on this preprint platform. I am very proud of our team and their determination to push under unusual circumstances (many stories to tell).
Rapid generation of circulating and mucosal decoy ACE2 using mRNA nanotherapeutics for the potential treatment of SARS-CoV-2 https://biorxiv.org/cgi/content/short/2020.07.24.205583v1 #bioRxiv